<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448042</url>
  </required_header>
  <id_info>
    <org_study_id>GO40311</org_study_id>
    <nct_id>NCT03448042</nct_id>
  </id_info>
  <brief_title>A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and pharmacokinetics of BTRC4017A in
      participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2
      (HER2)-expressing cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 29, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>From baseline through end of study (approximately 78 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of BTRC4017A</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1, up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration vs. Time Curve (AUC) of BTRC4017A</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1, up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of BTRC4017A</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1, up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Concentration (Cmin) of BTRC4017A</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1, up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of BTRC4017A</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1, up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of BTRC4017A</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1, up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR) as Determined by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)</measure>
    <time_frame>Baseline through the end of study (approximately 78 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first occurrence of a documented objective response to first documented disease progression or death from any cause, through the end of study (approximately 78 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) Levels of BTRC4017A</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1, up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">449</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned sequentially to escalating doses of BTRC4017A, up to the maximum tolerated dose (MTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BTRC4017A based on the MTD or maximum allowed dose (MAD) identified during dose escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTRC4017A</intervention_name>
    <description>BTRC4017A will be administered via IV infusion from until disease progression, intolerable toxicity, or any other discontinuation criteria are met.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Life expectancy of at least 12 weeks

          -  Adequate hematologic and end-organ function

          -  Acute, clinically significant treatment-related toxicity from prior therapy must have
             resolved to Grade &lt;/=1 prior to study entry

          -  Left Ventricular Ejection Fraction (LVEF) &gt;/=50%

        HER2-Expressing Breast Cancer-Specific Inclusion Criteria

          -  Locally tested, Human Epidermal Growth Factor Receptor 2 (HER2)-expressing BC

          -  Locally advanced or metastatic BC that has relapsed or is refractory to established
             therapies

        HER2-Expressing Gastric/Gastroesophageal (GEJ) Cancer-Specific Inclusion Criteria

          -  Adenocarcinoma of the stomach or GEJ with inoperable locally advanced or recurrent
             and/or metastatic disease, not amenable to curative therapy

          -  HER2-expressing tumor (primary tumor or metastasis) as assessed by local lab testing

          -  HER2-positive gastric/GEJ cancer must have received prior trastuzumab, cisplatin (or
             carboplatin or oxaliplatin or investigational platinum agent) and 5-fluorouracil
             (5-FU)/capecitabine

        HER2-Positive Solid Tumor Specific Inclusion Criteria

          -  HER2-positive tumor (primary tumor or metastasis) as assessed by local (non-central)
             laboratory testing

          -  Locally advanced, recurrent, or metastatic incurable malignancy that has progressed
             after at least one available standard therapy; or for whom standard therapy has proven
             to be ineffective or intolerable, or is considered inappropriate; or for whom a
             clinical trial of an investigational agent is a recognized standard of care; or for
             whom a clinical trial of an investigational agent is considered an acceptable
             treatment option

        Exclusion Criteria

          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within
             140 days after the last dose of BTRC4017A

          -  Significant cardiopulmonary dysfunction

          -  Known clinically significant liver disease

          -  Positive for acute or chronic Hepatitis B virus (HBV) infection

          -  Acute or chronic Hepatitis C virus (HCV) infection

          -  Human Immunodeficiency Virus (HIV) seropositivity

          -  Poorly controlled Type 2 diabetes mellitus

          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias

          -  Current treatment with medications that are well known to prolong the Q-wave/T-wave
             (QT) interval

          -  Known clinically significant liver disease

          -  Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active
             CNS metastases (progressing or requiring corticosteroids for symptomatic control)

          -  Leptomeningeal disease

          -  Spinal cord compression that has not definitively treated with surgery and/or
             radiation

          -  History of autoimmune disease

          -  Prior allogeneic stem cell or solid organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO40311 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

